The objective of this study was to determine the efficiency of UV blocking monomers in contact lenses in providing eye protection from UV radiation. The spectral transmission of 8 contact lenses (7 soft contact lenses: Precision UV, Acuvue 2, Surevue, Omega, Encore UV, Durasoft 3 and Lunelle UV and 1 rigid gas permeable contact lens: Boston 7) was evaluated by using a dual beam spectrophotometer. Durasoft 3, a non UV absorbent contact lens was used as the control. The results showed that Precision UV contact lens absorbed UV light up to wavelength of 380 nm, whereas Acuvue 2 and Surevue absorbed up to 360 nm only. Omega, Encore UV and Lunelle UV lenses absorbed UV light up to 335 nm with spectral transmission of Lunelle UV being the highest among all soft contact lenses tested, which was 17%. Boston 7 could absorb UV light up to 385 nm, but the amount of UV light transmitted was higher than soft lenses, which was 30%. Durasoft 3 only blocked UV light at 200-245 nm. Precision UV lens had better UV blocker characteristics than the other contact lenses tested. UV blocking soft contact lenses could be an alternative for spectacles in protecting internal ocular structures from UV radiation.
A 49-year old patient presented with symptoms of adrenal suppression following an attempt to
withdraw Depo-Provera or Depot Medroxyprogesterone Acetate (DMPA) injection. She had
been receiving DMPA injections for the past 16 years for contraception. She was initially
prescribed DMPA by her gynaecologist but later on began obtaining the medication directly
from a private pharmacy without prior consultation from her gynaecologist. Clinically, she had
been experiencing significant weight gain and appeared cushingoid. Blood investigations
confirmed partial adrenal suppression with presence of an adrenal incidentaloma. This case
reports a known side effect of DMPA but occurring at a much lower dose than previously
described. It also highlights the need to increase the awareness of the insidious side effect of
DMPA and to avoid unsupervised use of the drug.
This observational study examines the outcomes of pregnancies arising in women referred for infertility, where those who experienced threatened miscarriage were treated with medroxyprogesterone acetate (MPA) tablets. The 14-year study period covers comprehensive real-time data entries into the validated electronic database including details of the infertility management, pregnancy outcomes and any foetal anomalies among the infants, each being tracked and recorded. Of 4057 clinical pregnancies, 1343 received MPA for threatened miscarriage; 934 (69.6 %) of which continued to livebirths. These were compared with the remaining 2714 clinical pregnancies without threatened miscarriage or MPA and which resulted in 2075 (76.5 %) livebirths. There were 134 developmental abnormalities recorded among the 3009 livebirths of which 78 (2.6 %) were categorised appropriate for the Western Australian Developmental Abnormalities Register; WARDA. These comprised 55 in the MPA group, 36 of which were categorised as serious (being 2.7 % of clinical pregnancies and 3.9 % of births). In the group without MPA, there were 79 abnormalities, of which 42 were categorised as serious (being 1.7 % of clinical pregnancies and 2.2 % of births). Specifically, there were no cases of androgenisation noted among the female infants. The abnormality rates were low overall and well within the annual WARDA ranges. We cautiously suggest that oral MPA can be considered for studies throughout pregnancy including the early first trimester to assess a potential role in reducing miscarriage, as well as advanced pregnancies to evaluate a potential role in reducing stillbirths and preterm delivery.